Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023

Hannah Godfrey; Zachary Leibovit‐Reiben; Patrick Jedlowski; Rebecca Thiede

doi:10.1111/jdv.20197

journal article Jun 24, 2024

Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023

Hannah Godfrey

Zachary Leibovit‐Reiben Patrick Jedlowski Rebecca Thiede

Journal of the European Academy of Dermatology and Venereology Vol. 39 No. 2 · Wiley

View at Publisher Save 10.1111/jdv.20197

Topics

No keywords indexed for this article. Browse by subject →

References

9

[1]

10.1016/j.jaad.2023.04.022

[2]

10.1016/j.jaad.2017.01.060

[3]

Research C for DE and July – September 2023 | Potential signals of serious risks/new safety information identified by the FDA adverse event reporting system (FAERS). FDA [Internet]. 2024 Jan 2 [cited 2024 Jan 9]; Available from:https://www.fda.gov/drugs/questions‐and‐answers‐fdas‐adverse‐event‐reporting‐system‐faers/july‐september‐2023‐potential‐signals‐serious‐risksnew‐safety‐information‐identified‐fda‐adverse

[4]

10.1161/jaha.121.023811

[5]

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock, Carol Wysham, Juan P Frias et al.

The Lancet 10.1016/s0140-6736(21)01324-6

[6]

10.1016/s0140-6736(18)31773-2

[7]

10.1016/j.regpep.2006.02.007

[8]

Cohen‐Kurzrock RA "Bariatric surgery‐induced Telogen effluvium (Bar SITE): case report and a review of hair loss following weight loss surgery" Cureus (2021)

[9]

Case–non-case studies: Principle, methods, bias and interpretation

Jean-Luc Faillie

Therapies 10.1016/j.therap.2019.01.006

Cited By

33

Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications

Olivia M. Burke, Brianna Sa · 2025

Skin Appendage Disorders

Alopecia and Semaglutide: Connecting the Dots for Patient Safety

Diala Haykal · 2025

Journal of Cosmetic Dermatology

Metrics

33

Citations

9

References

Details

Published: Jun 24, 2024
Vol/Issue: 39(2)
License: View

Authors

H

Hannah Godfrey

University of Arizona College of Medicine–Tucson Tucson Arizona USA

Z

Zachary Leibovit‐Reiben

University of Arizona College of Medicine–Tucson Tucson Arizona USA

P

Patrick Jedlowski

Division of Dermatology University of Arizona College of Medicine–Tucson Tucson Arizona USA

R

Rebecca Thiede

Division of Dermatology University of Arizona College of Medicine–Tucson Tucson Arizona USA

Cite This Article

Hannah Godfrey, Zachary Leibovit‐Reiben, Patrick Jedlowski, et al. (2024). Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology, 39(2). https://doi.org/10.1111/jdv.20197

Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023

You May Also Like